BMS's Opdivo has been rejected by NICE for use in patients with advanced lung cancer, the cost-effectiveness watchdog saying its price is too high to merit routine use.

Opdivo (nivolumab) is a brand-name intravenous (IV) infusion prescribed for certain cancers. The cost of the drug, with and without insurance, can depend on several factors, such as whether Opdivo ...

Opdivo reduces the risk of death by 24% overall and 44% in patients with PD-L1 expression ≥1%, compared to placebo. Treatment-related side effects are more common with Opdivo, but no new safety ...

Opdivo plus AVD showed superior PFS and EFS compared to Adcetris plus AVD in patients with advanced Hodgkin lymphoma. The Opdivo regimen had a better side effect profile, with fewer severe side ...

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) plus Yervoy ...